Consistent with this, we observed the induction of key downstream UPR effectors, including ATF3, ATF4, and CHOP in a dose-dependent manner at the protein and mRNA levels upon treatment with JG-023 in CTCL cells (Figure 4A–C). The gene discussed is ATF4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.